Phthalates are widely used as plasticizers in consumer products such as building materials, toys, food packaging, cosmetics, and medical devices ([@r31]). The length of the alkyl chains gives rise to different molecular weights and functionality between the different types of phthalates. There is no covalent bond between phthalates and the plastics in which they are mixed, and phthalates are therefore easily released into the environment. Human exposure occurs through ingestion, inhalation, and dermal contact, with contaminated food considered to be the most important source of exposure to high-molecular weight phthalates (high-MWP; metabolites \> 250 Da) for the general population ([@r31]). The use of personal care products may increase exposure to low-MWP ([@r16]; [@r32]).

Phthalate metabolite concentrations in urine represent a measure of exposure from multiple sources and routes. The only study that has reported on the phthalate burden in a Norwegian population compared concentrations of phthalate metabolites in pregnant women from Norway, the Netherlands, and the United States and found comparable levels among these three groups of women, with estimated average daily intakes below the recommended maximum intake ([@r38]). Phthalates have also been found in abundance in indoor air particulate matter in Norwegian dwellings and schools ([@r29]), but so far no data on the body burden of phthalates in children in Norway are available.

In the last decade, several studies have reported associations between phthalate exposure and asthma and allergic disease ([@r14]). The findings differ among the phthalates, but most often the heavier phthalate metabolites have had impact on allergic disease development in animal models ([@r17]). In *in vitro* studies, the monoester metabolite of di(2-ethylhexyl) phthalate (DEHP), mono(2-ethylhexyl) phthalate (MEHP), induced a release of inflammatory mediators from lung cells, including tumor necrosis factor α ([@r30]), a pro-inflammatory cytokine that has been implicated in many aspects of the airway pathology of asthma. Several phthalates, including diisodecyl phthalate (DIDP) and phthalate metabolites such as MEHP, can activate peroxisome proliferator-activated receptors that participate in a range of cellular processes including positive and negative regulation of inflammation ([@r7]; [@r26]). In epidemiological studies, asthma and allergic diseases in children have been associated with house dust concentrations of several high-MWP that are often used in polyvinyl chloride (PVC) flooring ([@r4]; [@r20]). An early follow-up investigation of children from the same birth cohort evaluated in the present study reported that DEHP was the major phthalate in house dust ([@r27]) and that bronchial obstruction was associated with phthalate-containing PVC flooring and plastic surface materials at home ([@r15]). There are few reports on associations between biomarkers of phthalate exposure and respiratory outcomes, although one study reported an inverse association between urinary concentrations of monoethyl phthalate (MEP), a metabolite of diethyl phthalate (DEP), and lung function in adult men ([@r12]).

The aim of the present study was to explore the association between urinary concentrations of phthalate metabolites and current asthma in children.

Methods
=======

*Design and subjects*. The present cross-sectional study includes 10-year-old children from the Environment and Childhood Asthma (ECA) study in Oslo, Norway, which is described in detail elsewhere ([@r23]). Briefly, this birth cohort included 3,754 healthy infants born in Oslo during a 15-month period beginning 1 January 1992. The ECA study design involved clinical investigations of two main study populations within the birth cohort. Lung function was obtained in 802 infants shortly after birth ([@r25]). At 2 years of age, a nested case--control study aimed to include all children from the initial birth cohort who had recurrent (\> 1) or persistent (\> 4 weeks) doctor-confirmed bronchial obstruction, along with age-matched controls ([@r23]). Children with lung function measured at birth or who had participated in the case--control study at 2 years of age were invited to a 10-year follow-up; 1,019 (84%) children participated in the investigation \[see Supplemental Material, Figure S1 (<http://dx.doi.org/10.1289/ehp.1205256>)\].

Of the 1,019 children who participated in the 10-year follow-up, funds were available to analyze urine specimens for 623 children. Subjects who had current asthma at 10 years were preferentially sampled \[see Supplemental Material, Figure S1 (<http://dx.doi.org/10.1289/ehp.1205256>)\], yielding a higher prevalence of current asthma (21%) than in the 396 children who participated in the ECA 10-year follow-up but were not included in the present study (7%) (see Supplemental Material, Table S1). The 623 children in the present study had a slightly lower median age (10.7 vs. 10.8 years), a higher prevalence of atopic eczema (23% vs. 18%), a lower prevalence of allergic sensitization \[a positive skin prick test or elevated serum-specific IgE (≥ 0.35 kU/L) for at least one of the following allergens tested: house dust mites (*Dematophagoides pteronyssinus* and *D. farinae*), cat, dog, rabbit, German cockroach, birch, timothy, and mugworth pollen, *Cladosporium, Alternaria*, egg white, milk, peanut and codfish; 35% vs. 43%\] and were less likely to be firstborn (49% vs. 56%) than the 396 excluded children. The included children were comparable to the remainder of the original study cohort at birth with regard to most characteristics, but were less likely to be first-born (49% vs. 56%) and to be in a middle-income family (see Supplemental Material, Table S2).

The 10-year follow-up of the ECA study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate, and the biobank was registered in the Norwegian Biobank Registry (Oslo). The parents gave written informed consent for their child's participation in the study. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory was determined not to constitute engagement in human subjects research.

*Clinical examination and outcome definition*. The 10-year follow-up was performed between September 2001 and December 2004, and included a detailed parental structured interview, blood tests, skin prick tests (SPT) for allergic sensitization, spirometry, first morning urine sampling, and clinical examinations.

Current asthma ([@r24]) was defined by a history of asthma reported by the parent plus at least one of the following: reported dyspnea, chest tightness, and/or wheezing during the previous 12 months; reported use of asthma medication during the previous 12 months; or a positive exercise challenge test (a ≥ 10% decrease in forced expiratory volume in 1 sec compared with baseline, performed 2--7 days after the first visit).

*Urine collection and analyses*. The participants' first morning voids, collected at home in commercial polypropylene specimen collection containers, were aliquoted and frozen at --80ºC in 2 mL polypropylene tubes until they were shipped on dry ice to the CDC (Atlanta, GA, USA) for analysis. Three low-MWP metabolites \[molecular weight \< 250 Da; MEP, mono-*n*-butyl phthalate (MnBP), and monoisobutyl phthalate (MiBP)\] and eight high-MWP metabolites \[molecular weight \> 250 Da; monobenzyl phthalate (MBzP), mono(3-carboxypropyl) phthalate (MCPP), monocarboxyoctyl phthalate (MCOP), and monocarboxynonyl phthalate (MCNP), including four metabolites from DEHP: MEHP, mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP)\], were measured in the urine by online solid phase extraction coupled with high-performance liquid chromatography with isotope-dilution tandem mass spectrometry using a modification of the method reported by [@r33]. We multiplied the reported MEP and MBzP concentrations by 0.66 and 0.72, respectively, to correct for the inadequate purity of the analytic standards used. The lower-than-expected purity of the standards does not affect the performance of the analytical methods ([@r6]). After analyses, the urine samples were shipped on dry ice to the Norwegian Institute of Public Health. Urine specific gravity (SG) was measured by a handheld refractometer (Atago Urine Specific Gravity Refractometer PAL 10-S; ATAGO USA, Inc., Bellevue, WA, USA) after thawing and thorough mixing of the sample with a vortex shaker. The refractometer was calibrated with distilled water between each measurement.

*Statistical analyses*. SG-corrected urinary concentrations of phthalate metabolites were compared between girls and boys by analysis of variance (ANOVA). SG-corrected metabolite concentrations were calculated by the formula *P*~c~ = *P*\[(1.024-1)/(*SG*-1)\], where *P*~c~ is the SG-corrected phthalate metabolite concentration (micrograms per liter), *P* is the observed phthalate metabolite concentration, 1.024 is the median SG value in the study population, and *SG* is the specific gravity of the individual urine sample. For phthalate metabolite concentrations below the limit of detection (LOD), we used an imputed value equal to LOD/~√~^--^2. Correlations between the individual phthalate metabolites were evaluated using Spearman rank correlation coefficients (*r*~S~).

For current asthma, we fit logistic regression models by quartile concentration categories of the metabolites (lowest concentration category as reference) and a second model with phthalate metabolites as continuous variables (log~10~-transformed). SG was used as a covariate in the models. We modeled each of the individual phthalate metabolites separately, except for the DEHP metabolites (MEHP, MEOHP, MEHHP, and MECCP), which were combined into their micromolar sum (sum of the individual metabolites concentrations in micrograms per liter divided by the molecular weight of the metabolites) (ΣDEHP). We fitted additional models for the micromolar sums of high-molecular weight (Σhigh-MWP) and low-molecular weight (Σlow-MWP) metabolites. To test for trend across quartiles, we fitted the median quartile concentration values as a continuous variable in the logistic regression model.

Covariates were selected based on a directed acyclic graph \[see Supplemental Material, Figure S2 (<http://dx.doi.org/10.1289/ehp.1205256>)\] that included the following variables: sex, body mass index (BMI; age and sex adjusted), allergic sensitization in the child, parental smoking at home \[between the school age of the child (6--7 years) and the 10-year follow-up\], parental asthma (at child's birth), maternal education (at child's birth), and household income (at the 10-year follow-up). The minimal adjustment set for a total effect of phthalates on current asthma was sex, parental asthma, and household income. To examine the role of allergic sensitization in the association between phthalate metabolites and asthma, we fitted additional models after stratification by allergic sensitization. Finally, we tested for modification effects by sex, by adding interaction terms to the models. *p*-Values ≤ 0.05 were considered statistically significant. All statistical analyses were performed with Statistical Package for Social Sciences (SPSS version 19.0; IBM Inc., Chicago, IL, USA).

Results
=======

The present study is based on data and urinary concentrations of phthalate metabolites from 623 children (294 girls and 329 boys). The median age was 10.7 years (range, 8.8--12.5) at the time of urine collection and asthma status evaluation. Twenty-one percent met our definition of current asthma (82 boys and 46 girls), and asthma status was unavailable for one boy. The participating boys were more likely to have current rhinitis and to be allergically sensitized than girls, but they did not differ with regard to the presence of current atopic eczema or parental characteristics ([Table 1](#t1){ref-type="table"}).

###### 

Subject and parental characteristics for all participants, and for girls and boys separately (%).

  Characteristic                                                                                                                                                                                                                                                                                                                                                                                 All (n = 623)   Girls (n = 294)   Boys (n = 329)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------- ----------------
  Subjects                                                                                                                                                                                                                                                                                                                                                                                                                         
  BMI ≥ 85th percentilea                                                                                                                                                                                                                                                                                                                                                                         16              17                15
  Firstborn                                                                                                                                                                                                                                                                                                                                                                                      49              47                50
  Asthma, ever                                                                                                                                                                                                                                                                                                                                                                                   33              28\*              38
  Current asthma                                                                                                                                                                                                                                                                                                                                                                                 21              16\*              25
  Either SPT- or sIgE-positive                                                                                                                                                                                                                                                                                                                                                                   35              28\*              41
  Current rhinitisb                                                                                                                                                                                                                                                                                                                                                                              26              18\*              27
  Current atopic eczemab                                                                                                                                                                                                                                                                                                                                                                         23              23                24
  Parents                                                                                                                                                                                                                                                                                                                                                                                                                          
  Asthma                                                                                                                                                                                                                                                                                                                                                                                         14              13                15
  Asthma and/or rhinitis                                                                                                                                                                                                                                                                                                                                                                         36                                
  Maternal education (years)                                                                                                                                                                                                                                                                                                                                                                                                       
  ≤ 12                                                                                                                                                                                                                                                                                                                                                                                           47              50                45
  13--16                                                                                                                                                                                                                                                                                                                                                                                         31              30                33
  ≥ 17                                                                                                                                                                                                                                                                                                                                                                                           22              20                22
  Annual household income (1,000 NOK)                                                                                                                                                                                                                                                                                                                                                                                              
  \< 350                                                                                                                                                                                                                                                                                                                                                                                         13              12                14
  \> 350--560                                                                                                                                                                                                                                                                                                                                                                                    28              28                27
  \> 560--750                                                                                                                                                                                                                                                                                                                                                                                    30              85                31
  \> 750                                                                                                                                                                                                                                                                                                                                                                                         30              31                28
  Parental smoking at home                                                                                                                                                                                                                                                                                                                                                                       38              41                36
  NOK, Norwegian krone. Information was missing for firstborn (n = 31), asthma (ever and current) and rhinitis (n = 1), for SPT and sIgE combined (n = 21), current atopic eczema (n = 2), maternal education (n = 2), income (n = 6), parental smoking (n = 3). aBMI, age and sex adjusted. bSymptoms occurring during the last 12 months. \*p \< 0.01 for difference between girls and boys.                                     

*Body burden of phthalates*. Detectable concentrations were found for all phthalate metabolites except MCNP, MCPP, and MEHP, which were below the LOD in \< 4% of the urine samples ([Table 2](#t2){ref-type="table"}). Urine SG was higher in boys (1.024; range, 1.004--1.039) than in girls (1.023; range, 1.006--1.036, *p* \< 0.001). Strong correlations were observed between the urinary concentrations of MCOP and MCNP (*r*~S~ = 0.75, *p* \< 0.001) and between the oxidative metabolites of DEHP (MECPP, MEOHP, and MEHHP, all *r*~S~ \> 0.9, *p* \< 0.001) \[see Supplemental Material, Table S3 (<http://dx.doi.org/10.1289/ehp.1205256>)\].

###### 

Distribution of phthalate metabolites concentrations in urine for 623 Norwegian children (with uncorrected and SG-corrected values).

  Phthalate metabolite (µg/L)                                                                                                                                     LOD   n \< LOD   GM      Minimum   Percentile   Maximum                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ---------- ------- --------- ------------ --------- ------- ------- ------- -------
                                                                                                                                                                                                                                                    
  MEP                                                                                                                                                             0.4   0          60.9    8.5       16.7         32.6      56.7    94.4    360.2   6,006
  SG-corrected                                                                                                                                                                     64.4    7.0       19.9         35.3      56.3    101.1   320.2   5,339
  MnBP                                                                                                                                                            0.4   0          138.8   10.4      50.9         93.6      138.0   209.0   377.2   1,480
  SG-corrected                                                                                                                                                                     146.7   10.0      58.7         101.1     141.0   215.2   378.9   1,429
  MiBP                                                                                                                                                            0.2   0          53.6    3.1       15.6         31.4      49.2    88.4    231.0   1,480
  SG-corrected                                                                                                                                                                     57.0    6.3       18.8         34.6      50.1    90.5    239.6   1,480
  MBzP                                                                                                                                                            0.2   0          30.7    2.1       8.2          16.9      29.3    52.9    128.7   6,710
  SG-corrected                                                                                                                                                                     32.5    1.6       9.7          18.7      30.8    53.2    135.3   5,195
  MCPP                                                                                                                                                            0.2   23         7.8     LOD       2.6          4.6       7.5     12.8    26.2    384.0
  SG-corrected                                                                                                                                                                     8.2     LOD       3.6          5.4       7.9     12.5    24.7    307.2
  MEHP                                                                                                                                                            1.2   21         7.8     LOD       2.0          4.6       7.8     12.9    30.3    203.0
  SG-corrected                                                                                                                                                                     8.2     LOD       2.4          5.0       8.2     12.5    28.7    211.8
  MEOHP                                                                                                                                                           0.7   0          49.8    2.4       15.0         31.2      49.7    75.3    183.0   1,220
  SG-corrected                                                                                                                                                                     52.6    3.2       19.6         36.1      51.0    75.3    159.7   1,273
  MEHHP                                                                                                                                                           0.7   0          78.6    4.0       23.4         48.7      76.6    120.0   293.6   1,770
  SG-corrected                                                                                                                                                                     83.1    5.3       31.9         56.9      79.5    116.4   271.0   1,847
  MECPP                                                                                                                                                           0.6   0          101.2   11.3      29.1         62.2      98.2    162.0   380.4   3,520
  SG-corrected                                                                                                                                                                     106.9   11.9      38.9         71.7      105.0   153.2   343.2   3,673
  MCOP                                                                                                                                                            0.2   0          6.1     0.8       1.7          3.5       6.0     10.2    21.2    474.0
  SG-corrected                                                                                                                                                                     6.5     0.6       2.1          3.8       6.2     10.2    21.9    421.3
  MCNP                                                                                                                                                            0.2   23         2.2     LOD       0.6          1.4       2.1     3.5     8.3     168.0
  SG-corrected                                                                                                                                                                     2.3     LOD       0.7          1.5       2.2     3.6     7.8     162.8
  Phthalate sums (µmol/L)                                                                                                                                                                                                                           
  ∑low-MWPa                                                                                                                                                                        1.32    0.11      0.46         0.86      1.27    1.97    4.28    33.1
  SG-corrected                                                                                                                                                                     1.40    0.11      0.56         0.92      1.30    2.02    4.26    29.5
  ∑high-MWPb                                                                                                                                                                       1.05    0.14      0.36         0.66      1.01    1.58    3.68    33.1
  SG-corrected                                                                                                                                                                     1.10    0.11      0.45         0.76      1.06    1.51    3.17    29.0
  ∑DEHPc                                                                                                                                                                           0.81    0.08      0.26         0.50      0.79    1.23    2.86    22.4
  SG-corrected                                                                                                                                                                     0.85    0.10      0.34         0.58      0.82    1.18    2.69    23.3
  GM, geometric mean. a∑low-MWP: MEP, MnBP, and MiBP. b∑high-MWP: MBzP, MCNP, MCOP, MCPP, MEHP, MECPP, MEHHP, and MEOHP. c∑DEHP: MEHP, MECPP, MEHHP, and MEOHP.                                                                                     

Physical and demographic characteristics were associated with phthalate metabolite concentrations (data not shown). The concentrations of MBzP were higher in children with BMI ≥ 85th percentile, and in children of parents in the lowest household income category (≤ 299,000 Norwegian krone) and with maternal education ≤ 12 years. MEP concentrations were higher in children of mothers with ≤ 12 years of education, and higher in children with parents reporting smoking at home compared with other children \[geometric mean (GM) = 74 µg/L; 95% CI: 65, 84; and GM = 60 µg/L; 95% CI: 55, 65, respectively, *p* = 0.004\].

Compared with boys, girls had higher urinary concentrations of the low-MWP metabolites MnBP (*p* \< 0.001), MEP (*p* \< 0.001), and MiBP (*p* = 0.07) and of the high-MWP metabolite MCOP (*p* = 0.03) \[[Figure 1](#f1){ref-type="fig"}; see also Supplemental Material, Table S4 (<http://dx.doi.org/10.1289/ehp.1205256>)\].

![SG-adjusted phthalate metabolite concentrations (µg/L) in girls and boys. Values are GM with error bars for 95% CIs. \**p*\< 0.05. \*\**p*\< 0.001.](ehp.1205256.g001){#f1}

*Phthalates and asthma*. We observed statistically significant associations between the highest quartiles of MCNP and MCOP (in the adjusted analyses only) and current asthma ([Table 3](#t3){ref-type="table"}). The adjusted odds ratios (aORs) of current asthma increased with increasing concentration of MCOP per quartile (*p*~trend~ = 0.02) and with increasing concentration of MCNP (*p*~trend~ = 0.006) ([Table 3](#t3){ref-type="table"}). Girls had higher urinary concentrations of MCOP than boys ([Figure 1](#f1){ref-type="fig"}), but there was no statistically significant modification by sex with MCOP on current asthma (*p*~interaction~ \> 0.05). Phthalates were not associated with allergic sensitization (data not shown). When we stratified current asthma by allergic sensitization, the estimates for current asthma were similar for children without and with allergic sensitization, except for MCNP, which was associated with asthma among 392 children without allergic sensitization (aOR = 1.6; 95% CI: 1.1, 2.2) but not among 210 children with allergic sensitization (aOR = 1.1; 95% CI: 0.77, 1.15) \[see Supplemental Material, Table S5 (<http://dx.doi.org/10.1289/ehp.1205256>)\].

###### 

Crude and adjusted odds ratios of current asthma per concentration quartile and per log10 IQR increase in MEP, MnBP, MiBP, MBzP, MCPP, MCOP, and MCNP.

  Phthalate metabolite                                                                                                           Concentration (µg/L)   Noncases (n)   Cases (n)          Crude OR (95% CI)   aORa (95% CI)
  ------------------------------------------------------------------------------------------------------------------------------ ---------------------- -------------- ------------------ ------------------- ------------------
  MEP in quartiles                                                                                                               ≤ 32.6 (ref)           119            36                 1                   1
  \> 32.6--56.7                                                                                                                  125                    31             0.82 (0.47, 1.4)   0.97 (0.55, 1.7)    
  \> 56.7--94.4                                                                                                                  127                    29             0.76 (0.43, 1.4)   0.85 (0.47, 1.6)    
  \> 94.4                                                                                                                        123                    32             0.61 (0.50, 1.5)   0.99 (0.55, 1.8)    
  MEP per log10 IQR                                                                                                                                     494            128                0.82 (0.33, 2.1)    0.98 (0.39, 2.5)
  MnBP in quartiles                                                                                                              ≤ 93.6 (ref)           123            33                 1                   1
  \> 93.6--138                                                                                                                   124                    34             1.0 (0.60, 1.8)    1.2 (0.65, 2.0)     
  \> 138--209                                                                                                                    123                    32             0.99 (0.56, 1.8)   1.1 (0.62, 2.0)     
  \> 209                                                                                                                         124                    29             0.90 (0.49, 1.6)   0.96 (0.51, 1.8)    
  MnBP per log10 IQR                                                                                                                                    494            128                0.83 (0.63, 1.1)    0.85 (0.64, 1.1)
  MiBP in quartiles                                                                                                              ≤ 31.4 (ref)           130            28                 1                   1
  \> 31.4--49.2                                                                                                                  121                    33             1.3 (0.75, 2.4)    1.3 (0.74, 2.4)     
  \> 49.2--88.4                                                                                                                  123                    32             1.3 (0.72, 2.4)    1.4 (0.73, 2.5)     
  \> 88.4                                                                                                                        120                    35             1.5 (0.82, 2.7)    1.5 (0.80, 2.7)     
  MiBP per log10 IQR                                                                                                                                    494            128                1.1 (0.88, 1.5)     1.1 (0.87, 1.5)
  MBzP In quartiles                                                                                                              ≤ 16.9 (ref)           121            34                 1                   1
  \> 16.9--29.2                                                                                                                  130                    25             0.70 (0.39, 1.3)   0.70 (0.39, 1.3)    
  \> 29.2--52.9                                                                                                                  128                    27             0.79 (0.44, 1.4)   0.83 (0.45, 1.5)    
  \> 52.9                                                                                                                        115                    42             1.4 (0.81, 2.4)    1.3 (0.75, 2.4)     
  MBzP per log10 IQR                                                                                                                                    494            128                1.2 (0.91, 1.5)     1.2 (0.88, 1.5)
  MCPP in quartiles                                                                                                              ≤ 4.6 (ref)            121            36                 1                   1
  \> 4.6--7.5                                                                                                                    132                    23             0.61 (0.34, 1.1)   0.60 (0.33, 1.1)    
  \> 7.5--12.8                                                                                                                   124                    33             0.95 (0.54, 1.7)   1.0 (0.57, 1.9)     
  \> 12.8                                                                                                                        117                    36             1.1 (0.62, 2.1)    1.2 (0.63, 2.1)     
  MCPP per log10 IQR                                                                                                                                    494            128                0.99 (0.75, 1.3)    0.99 (0.74, 1.3)
  MCOP in quartiles                                                                                                              ≤ 3.5 (ref)            127            30                 1                   1
  \> 3.5--6.0                                                                                                                    131                    27             0.93 (0.52, 1.7)   1.0 (0.60, 1.9)     
  \> 6.0--10.2                                                                                                                   123                    31             1.2 (0.65, 2.1)    1.2 (0.67, 2.3)     
  \> 10.2                                                                                                                        113                    40             1.7 (0.94, 3.0)    1.9 (1.0, 3.3)      
  MCOP per log10 IQR                                                                                                                                    494            128                1.3 (0.96, 1.6)     1.3 (0.98, 1.7)
  MCNP in quartiles                                                                                                              ≤ 1.4 (ref)            145            29                 1                   1
  \> 1.4--2.1                                                                                                                    113                    26             1.2 (0.7, 2.2)     1.2 (0.63, 2.2)     
  \> 2.1--3.5                                                                                                                    123                    31             1.4 (0.8, 2.5)     1.5 (0.84, 2.8)     
  \> 3.5                                                                                                                         113                    42             2.2 (1.2, 3.9)     2.2 (1.2, 4.0)      
  MCNP per log10 IQR                                                                                                                                    494            128                1.3 (1.0, 1.6)      1.3 (1.0, 1.7)
  Abbreviations: IQR, interquartile range; ref, reference. aAdjusted for urine SG, sex, parental asthma, and household income.                                                                                

Sex modified the association between ΣDEHP (in quartiles) and current asthma (overall *p*~interaction~ = 0.03, and *p* \< 0.05 for each of the quartiles). The aORs for current asthma in girls for the three highest concentration categories of ΣDEHP were 3.9 (95% CI: 1.2, 12.5), 5.9 (95% CI: 1.8, 19.2), and 4.6 (95% CI: 1.3, 16.3), *p*~trend~ = 0.04. The aORs for current asthma in boys by quartile concentrations of ΣDEHP were 0.54 (95% CI: 0.25, 1.19), 0.68 (95% CI: 0.31, 1.48), and 1.07 (95% CI: 0.50, 2.3) \[see Supplemental Material, Figure S3 (<http://dx.doi.org/10.1289/ehp.1205256>)\]. When ΣDEHP was used as a continuous variable in the model, no sex modification between ΣDEHP and current asthma was observed (*p*~interaction~ = 0.2), aOR of 1.2 (95% CI: 0.82, 1.83) per IQR log~10~ unit increase in ΣDEHP for girls and 0.87 (95% CI: 0.62, 1.2) for boys.

Current asthma was not statistically significantly associated with urinary concentrations of MEP, MnBP, MiBP, MBzP, or MCPP ([Table 3](#t3){ref-type="table"}). The ORs for current asthma increased by quartiles for ΣDEHP and Σhigh-MWP ([Table 4](#t4){ref-type="table"}), but the individual estimates were not statistically significant.

###### 

Crude and adjusted odds ratios of current asthma per concentration quartile and per log10 IQR increase in ΣDEHP, Σlow-MWP, and Σhigh-MWP.

  Phthalate metabolite sum                                                                                                                                                                                                                                                 Concentration (µmol/L)   Noncases (n)   Cases (n)          OR (95% CI)        aORa (95% CI)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ -------------- ------------------ ------------------ ------------------
  ΣDEHPb In quartiles                                                                                                                                                                                                                                                      ≤ 0.50 (ref)             123            31                 1                  1
  \> 0.50--0.79                                                                                                                                                                                                                                                            129                      27             0.90 (0.50, 1.6)   1.1 (0.65, 1.9)    
  \> 0.79--1.23                                                                                                                                                                                                                                                            122                      34             1.3 (0.69, 2.3)    1.4 (0.75, 2.6)    
  \> 1.23                                                                                                                                                                                                                                                                  120                      36             1.4 (0.75, 2.7)    1.6 (0.83, 3.2)    
  ΣDEHP per log10 IQR                                                                                                                                                                                                                                                                               494            128                0.96 (0.73, 1.3)   0.99 (0.75, 1.3)
  Σlow-MWPc in quartiles                                                                                                                                                                                                                                                   ≤ 0.85 (ref)             121            34                 1                  1
  \> 0.85--1.26                                                                                                                                                                                                                                                            126                      28             0.81 (0.46, 1.4)   0.83 (0.46, 1.5)   
  \> 1.26--1.97                                                                                                                                                                                                                                                            121                      35             1.1 (0.60, 1.9)    1.3 (0.71, 2.3)    
  \> 1.97                                                                                                                                                                                                                                                                  125                      31             0.92 (0.51, 1.7)   0.95 (0.51, 1.8)   
  Σlow-MWP per log10 IQR                                                                                                                                                                                                                                                                            494            128                0.98 (0.76, 1.3)   1.0 (0.77, 1.3)
  Σhigh-MWPd in quartiles                                                                                                                                                                                                                                                  ≤ 0.66 (ref)             125            29                 1                  1
  \> 0.66--1.0                                                                                                                                                                                                                                                             126                      29             1.1 (0.61, 2.0)    1.2 (0.65, 2.2)    
  \> 1.0--1.56                                                                                                                                                                                                                                                             123                      32             1.3 (0.72, 2.5)    1.4 (0.72, 2.6)    
  \> 1.56                                                                                                                                                                                                                                                                  118                      38             1.8 (0.92, 3.4)    1,8 (0.92, 3.6)    
  Σhigh-MWP per log10 IQR                                                                                                                                                                                                                                                                           494            128                1.0 (0.76, 1.3)    1.0 (0.77, 1.4)
  Abbreviations: IQR, interquartile range; ref, reference. aAdjusted for urine SG, sex, parental asthma, and household income. b∑DEHP: MEHP, MECPP, MEHHP, and MEOHP. c∑Low-MWP: MEP, MnBP, and MiBP. d∑High-MWP: MBzP, MCNP, MCOP, MCPP, MEHP, MECPP, MEHHP, and MEOHP.                                                                                 

Discussion
==========

The body burden of phthalates as determined by urinary concentrations of their metabolites was measurable in all study subjects in this Norwegian population in 2001--2004. Girls had higher urinary concentrations of the low-MWP metabolites than boys. We found associations between current asthma and the highest quartiles of MCOP and MCNP, metabolites of diisononyl phthalate (DINP) and DIDP, respectively, but not with any of the other phthalate metabolites evaluated in this study.

The present study population had, by design, a high prevalence of current asthma, and is not representative of the general population of Norwegian 10-year-old children. However, the concentrations of most phthalate metabolites were similar to those in previous reports for children in Europe and the United States. The urinary concentrations of the four DEHP metabolites were comparable to concentrations reported for children 6--11 years old from the 2001--2004 U.S. National Health and Nutrition Examination Survey (NHANES) ([@r6]), and MCOP and MCNP levels were comparable to those in adolescents in NHANES 2005--2006 ([@r5]). DEHP, MiBP, MnBP, and MCOP concentrations in the Norwegian children were comparable to levels reported for German children ([@r3]; [@r18], [@r19]). However, caution should be taken when comparing studies, as differences in use of spot (NHANES) versus first morning voids (the present study), may affect the levels of phthalate metabolites in urine ([@r28]).

In the present study, the concentration of MBzP was associated with low household income, low maternal education level, and a BMI \> 85th percentile---characteristics that are highly associated with each other. The reasons for a higher concentration of MBzP within these groups are unknown, but may be related to differences in diet, housing characteristics, or other factors. The concentration of MEP was higher in children of parents who smoked at home and in children whose mothers had the lowest level of education. Higher MEP concentrations were previously reported among male smokers compared with male nonsmokers ([@r8]).

Girls had higher urinary concentrations of the low-MWP metabolites MnBP and MEP than did boys. Similar differences have been reported for adults ([@r32]) and for German students (age range, 20--29 years) for MnBP and MiBP ([@r37]), whereas among healthy Danish children and adolescents (6--21 years of age), boys had significantly higher levels of MiBP and MnBP than girls ([@r9]). In one previous study that measured four phthalates in particulate matter in indoor air samples from dwellings, schools, and kindergartens in Norway, di-*n*-butyl phthalate (DnBP) concentrations were higher in all locations compared with butylbenzyl phthalate (BBzP), DEHP, and dicyclohexyl phthalate ([@r29]). Furthermore, significant correlations between personal air levels of DEP, DnBP, and BBzP and urinary concentrations of their corresponding metabolites have been reported ([@r1]), suggesting that inhalation may be an important pathway of exposure to low-MWP. Reported sex differences in MEP concentrations in adults ([@r32]) have usually been explained by the use of cosmetics and body-care products, and perfume use has been suggested to be a significant source of DEP exposure in women ([@r16]). This relation could however not be ascertained in the present study as use of personal care products was not assessed.

The metabolites MCOP and MCNP from the high-MWP DINP and DIDP, respectively, were modestly associated with current asthma in the present study. The associations were statistically significant only for the highest concentrations of MCOP and MCNP, but with a monotonic increasing trend by quartiles of MCOP and MCNP. In toxicological studies, DINP has been found to affect reproductive outcomes and the development of the male reproductive tract, and DIDP to produce rodent liver effects ([@r7])---but these effects are observed mainly with exposure levels that are much higher than estimated human exposure. Experimental studies of DIDP and DINP with a focus on respiratory outcomes are so far lacking. Given the paucity of the data, it is also difficult to speculate about why the association between concentrations of MCNP and current asthma appears to be strongest among the nonsensitized children in our study. The strong correlation between MCOP and MCNP suggests similar sources of exposure to the parent compounds, which are both used primarily as plasticizers of PVC and may be used in flooring, wall coverings, building materials, heat-resistant electrical cords, car interiors, and toys. Previous studies have reported associations between exposure to PVC-containing interior surface materials ([@r15], [@r13]; [@r22]) and high-MWP in dust with asthma and respiratory outcomes ([@r4]; [@r20]), but DINP and DIDP have usually not been measured in environmental samples.

Previous studies have reported associations between house dust concentrations of DEHP and asthma and wheeze in children ([@r4]; [@r20]), but none have reported evidence of differences by sex. However, due to the small numbers of observations after stratifying by sex, estimates were imprecise, increasing the uncertainty about the accuracy of the point estimates. In one early publication based on the 2-year follow-up of the children in the ECA study, DEHP was identified as the major source of phthalate exposure, both in house dust and particulate matter ([@r27]). DEHP, which was the most commonly used phthalate plasticizer for many years, is now being replaced by DINP and DIDP ([@r36]).

When assessing associations between phthalate biomarkers and respiratory outcomes, one concern is individuals who receive pulmonary therapy through PVC tubing that may contain DEHP ([@r34]). However, very few children in the ECA study had severe asthma (10 of 154 with current asthma in the 10-year follow-up) ([@r21]), and the use of asthma medication as well as hospitalizations have been thoroughly reported in the parental interview at the 10-year follow-up investigation. We did not find any statistically significant associations by ANOVA between SG-adjusted phthalate metabolite concentrations and use of asthma medication (leukotriene agonists, β-2 agonists, and inhaled corticosteroids) during the 14 days before urine collection (results not shown). Although use of asthma medication did not explain the association with current asthma, the possibility of reverse causation cannot be ruled out given the cross-sectional design of this study. Although DIDP and DINP are used mainly as plasticizers of PVC---highlighted as a possible explanation for the associations reported between high-MWP in indoor dust and asthma ([@r14])---most of the body burden of high-MWP metabolites is likely to be derived from contaminated foods ([@r31]). We cannot exclude the possibility that differences in phthalate metabolite levels are caused by differences in sources of exposure, such as diet and personal care products.

In the present study, we measured the oxidative metabolites MECPP, MEHHP, and MEOHP from DEHP and the oxidative metabolites MCOP and MCNP from DINP and DIDP, respectively. The oxidized phthalate metabolites are not susceptible to external contamination, and have longer half-lives than the monoesters and are therefore suggested to be suitable for capturing the average background exposure. Our measurements are based on a single urine sample only, and although spot urine samples and 24-hr urine samples produced comparable estimates of daily DEHP intake ([@r35]), and a single urine measurement may be predictive of short-term exposure ([@r11]), the short biological half-life of phthalates make measurements based on single urine samples less representative of exposure over longer intervals ([@r10]; [@r28]). We could not evaluate the possibility of metabolites degradation during long-term storage of our samples. However, phthalate metabolites are considered chemically stable and the high correlation between the concentrations of DEHP metabolites is a good indicator of stability ([@r2]). Whereas other studies to date have looked at a few high-MWPs (mainly DEHP and BBzP), we assessed a wide selection of high-MWP in association with current asthma in children.

Conclusions
===========

Urinary concentrations of phthalate metabolites in Norwegian children were comparable to concentrations reported from children in other European countries and in the United States. Current asthma was modestly associated with urinary concentrations of DINP and DIDP metabolites. Although our findings add to the increasing literature on high-MWP exposure and asthma, the results of this study should be interpreted with caution due the cross-sectional design and the short half-life of the phthalate metabolites.
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